{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:18:30Z","timestamp":1793305110186,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diabres.2025.112918","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:51:08Z","timestamp":1758765068000},"page":"112918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3290-1909","authenticated-orcid":false,"given":"Jheng-Yan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tsung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1723-828X","authenticated-orcid":false,"given":"Yu-Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.diabres.2025.112918_b0005","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2025.112918_b0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.diabres.2025.112918_b0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.diabres.2025.112918_b0020","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.diabres.2025.112918_b0025","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"J Am Med Assoc"},{"issue":"6","key":"10.1016\/j.diabres.2025.112918_b0030","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112918_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2025.112918_b0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12916-022-02716-3","article-title":"Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease","volume":"21","author":"Chung","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.diabres.2025.112918_b0045","first-page":"S6","article-title":"Standards of care in diabetes-2025","volume":"48","author":"Summary of Revisions","year":"2025","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2025.112918_b0050","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","article-title":"Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial","volume":"59","author":"Smits","year":"2016","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.diabres.2025.112918_b0055","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S1499-3872(13)60092-2","article-title":"Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review","volume":"12","author":"Olaywi","year":"2013","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"10","key":"10.1016\/j.diabres.2025.112918_b0060","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/hepr.12834","article-title":"Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus","volume":"47","author":"Seko","year":"2017","journal-title":"Hepatol Res"},{"issue":"3","key":"10.1016\/j.diabres.2025.112918_b0065","first-page":"843","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Placebo-Controlled Clinical Trial Diabetes Ther"},{"issue":"2","key":"10.1016\/j.diabres.2025.112918_b0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"10.1016\/j.diabres.2025.112918_b0075","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2025.112918_b0080","article-title":"Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study","author":"Kuo","year":"2024","journal-title":"Hep Intl"},{"key":"10.1016\/j.diabres.2025.112918_b0085","first-page":"1","article-title":"Clinical outcomes in diabetic patients with zinc deficiency: a multi-institutional population-based study","author":"Wu","year":"2025","journal-title":"J Am Nutr Assoc"},{"key":"10.1016\/j.diabres.2025.112918_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112083","article-title":"Tirzepatide and major adverse limb events: insights from a multicenter real-world analysis in PAD and diabetes patients","volume":"222","author":"Wu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2025.112918_b0095","article-title":"Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: based on food and drug administration adverse event report system database","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112918_b0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50050","article-title":"Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease","volume":"7","author":"Pan","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.diabres.2025.112918_b0105","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4103\/ijem.IJEM_159_17","article-title":"Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus","volume":"22","author":"Unnikrishnan","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.diabres.2025.112918_b0110","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/apt.18502","article-title":"Glucagon-like peptide-1 receptor agonists and liver outcomes in patients with MASLD and type 2 diabetes","volume":"61","author":"Kuo","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.diabres.2025.112918_b0115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","article-title":"Landmark analysis: a primer","volume":"26","author":"Morgan","year":"2019","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"10.1016\/j.diabres.2025.112918_b0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5694\/mja11.10627","article-title":"Concepts in epidemiology: the cohort effect","volume":"196","author":"Mills","year":"2012","journal-title":"Med J Aust"},{"issue":"9","key":"10.1016\/j.diabres.2025.112918_b0125","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/bcp.14024","article-title":"Pharmacoepidemiology: using randomised control trials and observational studies in clinical decision-making","volume":"85","author":"Caparrotta","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"15","key":"10.1016\/j.diabres.2025.112918_b0130","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/sim.4780141510","article-title":"Graphical methods for assessing violations of the proportional hazards assumption in Cox regression","volume":"14","author":"Hess","year":"1995","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.diabres.2025.112918_b0135","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the e-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.diabres.2025.112918_b0140","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/jdi.13237","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"11","author":"Xing","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2025.112918_b0145","article-title":"Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in asian patients with type 2 diabetes: a meta-analysis","volume":"11","author":"Wong","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.diabres.2025.112918_b0150","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5114\/ceh.2020.102173","article-title":"SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review","volume":"6","author":"Dwinata","year":"2020","journal-title":"Clin Exp Hepatol"},{"issue":"4","key":"10.1016\/j.diabres.2025.112918_b0155","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1016\/j.diabres.2025.112918_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.orcp.2016.03.009","article-title":"Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity","volume":"12","author":"Jorge","year":"2018","journal-title":"Obes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.diabres.2025.112918_b0165","first-page":"39","article-title":"Liver fibrosis in the context of nonalcoholic steatohepatitis: the role of adipokines","volume":"64","author":"Dim","year":"2018","journal-title":"Minerva Gastroenterol Dietol"},{"issue":"11","key":"10.1016\/j.diabres.2025.112918_b0170","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/CIRCRESAHA.119.315896","article-title":"Metabolic inflammation and insulin resistance in obesity","volume":"126","author":"Wu","year":"2020","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.diabres.2025.112918_b0175","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.diabres.2025.112918_b0180","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/hep.23594","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection","volume":"51","author":"Starley","year":"2010","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.diabres.2025.112918_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105634","article-title":"Role of sodium-glucose co-transporter 2 inhibitors in the regulation of inflammatory processes in animal models","volume":"23","author":"Feij\u00f3o-Band\u00edn","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2025.112918_b0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/biom14040476","article-title":"Innate immunity and MASLD","volume":"14","author":"Meyer","year":"2024","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.diabres.2025.112918_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054405","article-title":"Clinical study of metabolic parameters, leptin and the SGLT2 inhibitor empagliflozin among patients with obesity and Type 2 diabetes","volume":"24","author":"Szekeres","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.diabres.2025.112918_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11020087","article-title":"The effects of SGLT2 inhibitors on lipid metabolism","volume":"11","author":"Szekeres","year":"2021","journal-title":"Metabolites"},{"issue":"3","key":"10.1016\/j.diabres.2025.112918_b0205","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-23-0365","article-title":"Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence","volume":"261","author":"McGlone","year":"2024","journal-title":"J Endocrinol"},{"issue":"12","key":"10.1016\/j.diabres.2025.112918_b0210","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2337\/db20-0369","article-title":"The role of glucagon in the acute therapeutic effects of SGLT2 inhibition","volume":"69","author":"H\u00e6dersdal","year":"2020","journal-title":"Diabetes"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:18:09Z","timestamp":1764080289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725009325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":42,"alternative-id":["S0168822725009325"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112918","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112918"}}